| Dr Drew Michael Keister, MD | |
|
1730 Chew St, Allentown, PA 18104-5549 | |
| (610) 969-3500 | |
| (610) 969-3509 |
| Full Name | Dr Drew Michael Keister |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 1730 Chew St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407849862 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD434233 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Schuylkill Health System Medical Group, Inc. | 0840285532 | 87 |
| Valley Health Partners Community Health Center | 4284065327 | 59 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
| Entity Name | Family Care Centers Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669563037 PECOS PAC ID: 5395649347 Enrollment ID: O20031121000497 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
| Entity Name | Schuylkill Health System Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588603567 PECOS PAC ID: 0840285532 Enrollment ID: O20040420001197 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
| Entity Name | Neighborhood Health Centers Of The Lehigh Valley |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619106382 PECOS PAC ID: 2961537352 Enrollment ID: O20100526000092 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
| Entity Name | Valley Health Partners Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770118648 PECOS PAC ID: 4284065327 Enrollment ID: O20200505003199 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Drew Michael Keister, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: (484) 884-4500 | Dr Drew Michael Keister, MD 1730 Chew St, Allentown, PA 18104-5549 Ph: (610) 969-3500 |
News Archive
The equivalent of just two and a half glasses of orange juice a day could reverse obesity and reduce the risk of heart disease and diabetes.
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.
A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.
Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.
After more than 20 years of research on the best treatment for full-term infants affected by oxygen deprivation during the birthing process, Seetha Shankaran, M.D., neonatologist at DMC's Children's Hospital of Michigan and Hutzel Women's Hospital, served as the lead investigator in a definitive Journal of the American Medical Association study that documented the safest depth and duration of body-cooling to minimize injury from hypoxic ischemic encephalopathy (HIE) in newborns.
› Verified 9 days ago
Dr. Xander Arwand, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd Ste 110, Allentown, PA 18103 Phone: 610-402-8900 Fax: 610-402-5656 | |
John E Connelly, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 501 N 17th St, Suite # 108, Allentown, PA 18104 Phone: 610-434-4760 Fax: 610-820-9122 | |
Dr. Ann Marie Lam, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1251 S Cedar Crest Blvd, Suite 102 A, Allentown, PA 18103 Phone: 610-402-3940 Fax: 610-102-3950 | |
Leyland Robinson, Family Medicine Medicare: Medicare Enrolled Practice Location: 3435 Winchester Rd Ste 201, Allentown, PA 18104 Phone: 610-402-0100 | |
Dr. Joseph Thomas Termini, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 942 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-433-0404 | |
Madhavi Capoccia, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 250 Cetronia Rd, Suite 115, Allentown, PA 18104 Phone: 610-395-0307 Fax: 610-395-0950 | |
Pavel Enrique Terreros, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1447 W Hamilton St, Allentown, PA 18102 Phone: 610-434-4445 |